A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris

Trial Profile

A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2013

At a glance

  • Drugs Trifarotene (Primary) ; Tazarotene
  • Indications Acne vulgaris
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 17 Dec 2012 Planned end date changed from 1 May 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top